SCHEMBL3577983

SCHEMBL3577983

Cc1ccc(S(=O)(=O)OCCCCC(C)CCCC(C)CCCC(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
CA1 P00915 1/20 0.38
PSMD10 O75832 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP24A1 Q07973 2/20 0.36
CA2 P00918 1/20 0.36
STAT3 P40763 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575734 1.00 LMNA (0.40) LMNACA12CA9CA1PSMD10
SCHEMBL2417234 0.94 ALDH1A1 (0.41) CA12CA9CA1PSMD10ALDH1A1
SCHEMBL10759972 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL11363251 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL10538441 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL9485780 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL3581029 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL10725680 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL10538451 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10
SCHEMBL1769852 0.93 CA12 (0.38) LMNACA12CA9CA1PSMD10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846903-B2 cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2010-12-07 US disclosed
US-20080113923-A1 Type II Cubic Liquid Crystal Composition NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) 2008-05-15 US disclosed
EP-1813287-A1 TYPE II CUBIC LIQUID CRYSTAL COMPOSITION National Institute of Advanced Industrial Science and Technology (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113923-A1 Type II Cubic Liquid Crystal Composition AQP1, AQP3, SCO2 LMNA 1444/4885CA12 34/4885CA9 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.